Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719918 | 0.90 | PTGS1 (0.39) | PTGS2KIF11PTGS1 | |
| SCHEMBL718959 | 0.88 | NAAA (0.48) | PTGS2NAAAKIF11CARM1PRMT6 | |
| SCHEMBL720365 | 0.80 | KIF11 (0.44) | PTGS2KIF11PTGS1 | |
| SCHEMBL718908 | 0.80 | PTGS2 (0.46) | PTGS2KIF11PTGS1 | |
| SCHEMBL720234 | 0.80 | KIF11 (0.44) | PTGS2KIF11PTGS1 | |
| SCHEMBL720225 | 0.77 | GPR119 (0.44) | PTGS2PTGS1 | |
| SCHEMBL719524 | 0.76 | KDM1A (0.44) | CARM1PRMT6OPRM1OPRL1 | |
| SCHEMBL719074 | 0.74 | PTGS2 (0.37) | PTGS2KIF11PTGS1 | |
| SCHEMBL719735 | 0.74 | NAAA (0.38) | PTGS2NAAAKIF11PTGS1 | |
| SCHEMBL904009 | 0.74 | SLC6A2 (0.45) | PTGS2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | GPR119, GLP1R, GIPR | PTGS2 1777/4885NAAA 2254/4885KIF11 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.